Listen: Remdesivir’s controversial cost, early vaccine promise, and AI at the end of life

What’s a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care?

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we dig into the long-awaited price for Gilead Sciences’ Covid-19 treatment and break down the disparate reactions from lawmakers, activists, and Wall Street analysts. Then, STAT’s Matthew Herper joins us to discuss some of the first detailed data on a potential vaccine for the novel coronavirus. Finally, we talk about a new use for AI: nudging clinicians to broach delicate conversations with patients about their end-of-life goals and wishes.

For more on what we cover, here’s the remdesivir news; here’s more on the vaccine data; here’s the story on AI; and here’s the latest in STAT’s coronavirus coverage.

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].